F8 and hemophilia A: Several FVIII preparations are available for the treatment of Hemophilia A, and they differ in respect to B-domain deletion, residual/molecular composition, and glycosylation patterns, influencing properties such as immunogenicity, metabolism, and functionality [31–34].